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ABSTRACT 
 
Post-translation modifications play a crucial role in coordinating the cellular response to DNA 
damage. 
Double strand DNA breaks (DSBs) trigger the activation of ATM and Chk2 kinases, which 
represent the primary transducers in the signalling cascade. Among the high number of 
phosphorylated proteins, our attention was focused on Che-1, a novel ATM and Chk2 
substrate whose role in DNA damage response has been recently shown. Phosphorylated Che-
1 accumulates and promotes transcription of p53 and p53-responsive genes, which are critical 
for the maintenance of G2 arrest and for DNA repair processes
 
. 
Poly(ADP-ribosyl)ation is a post-translational modification that shows an emerging role in the 
signal transduction to the DDR machinery. Poly(ADP-ribose) polymerase 1 (PARP-1), the 
main enzyme involved in this modification, is recruited on DNA lesions and catalyzes the 
synthesis of ADP-ribose polymers (PAR) on itself and on target proteins. In particular, a 
recent work demonstrated that PAR synthesis at DSBs sites is necessary to recruit ATM 
kinase, which can interact non-covalently with PAR. 
In this study we showed that poly(ADP-ribosyl)ation, beyond phosphorylation, is involved in 
the regulation of Che-1 stabilization following DNA damage. We demonstrated that Che-1 
accumulation upon doxorubicin treatment is reduced after inhibition of PARP activity in 
HCT116 cells and in PARP-1 knock-out or silenced cells. In accordance, impairment in Che-1 
accumulation by PARP inhibition reduced Che-1 occupancy at p21 promoter and affected the 
expression of the corresponding gene. Epistasis experiments showed that the effect of 
poly(ADP-ribosyl)ation on Che-1 stabilization is independent from ATM kinase activity. 
Indeed we demonstrated that Che-1 protein co-immunoprecipitates with PAR and that PARP-
1 directly interacts with Che-1, promoting its modification in vitro and in vivo. 
Altogether, these findings suggest that poly(ADP-ribosyl)ation of Che-1 represents a 
mechanism enabling the precise control over the level of Che-1 protein in response to DNA 
damage. 
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INTRODUCTION 
 
 
A unique insurance policy for the cell: the DNA damage response  
 
Each of the cells in our body receives tens of thousands of DNA lesions every day (Lindahl 
and Barnes, 2000). Environmental sources of damage include ultraviolet (UV) light, ionizing 
radiations (IR) and chemicals in tobacco smoke or in contaminated food. However, much of 
DNA damage arises from endogenous sources as a consequence of normal cellular 
metabolism. DNA mismatches and breaks are occasionally produced during replication or 
following abortive topoisomerase activity. Moreover, reactive oxygen compounds are by-
products of oxidative respiration or are produced, together with nitrogen compounds, during 
inflammation processes (Kawanishi et al., 2006).  
DNA lesions can impair replication and transcription reactions and produce mutations and 
genomic rearrangements. As a consequence, they can induce senescence or cell death and 
affect organism’s development and ageing. Moreover, genomic instability greatly predisposes 
the organism to immunodeficiency, neurological disorders and cancer (Hakem, 2008; Subba 
Rao, 2007; Thoms et al., 2007). 
To cope with DNA damage and prevent its propagation across cell divisions, cells have 
evolved a special “insurance policy” commonly referred as DNA damage response (DDR) 
(Harper and Elledge, 2007). The DDR is a complex and versatile network of mechanisms that 
coordinates the physical detection of the damage with the activation of signalling pathways 
highly interconnected and regulated in space and time. These pathways control the relaxation 
of chromatin structure to facilitate the repair, the recruitment and the activation of repair 
factors to the DNA damage site and the concomitant block of cell cycle by checkpoints. If the 
damage is too intense, DDR activates senescence or the apoptotic program (Figure 1). 
Distinct DNA repair mechanisms deal with the wide variety of structurally different DNA 
lesions (Figure 2) (Hakem, 2008). The direct lesion reversal repairs O
6
-alkylguanine induced 
by alkylating agents, while the small insertions and deletions produced during replication are 
the substrate of the mismatch repair. Helix distorting lesions and base damage, the most 
common insult to DNA, are repaired respectively by the nucleotide excision repair and the 
base excision repair. Although less frequent than other lesions, double-strand DNA breaks 
(DSBs) are the most cytotoxic of all DNA lesions. DSBs are caused by IR and radiomimetic 
compounds, but are also generated when the replication machinery encounters single strand 
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Figure 1. The DNA damage response. The cell response to DNA insults (survival or death pathways) 
depends on the type and the extent of the damage. A complex network of signalling pathways regulates these 
choices at the molecular level. Failure in correct repair can lead to malignant transformation (adapted from 
Shiloh 2003). 
  
 
breaks (SSBs). Two distinct but partially complementary pathways act to repair DSBs: the 
non-homologous end-joing, an error-prone mechanism in which the two DNA ends are ligated 
together, and the homologous recombination, which relies on the presence of a homologous 
 6 
DNA molecule that can be copied to repair the damage. Although more accurate than NHEJ, 
HR operates only at the S or G2 phase of the cell cycle, and NHEJ is the predominant 
mechanism of DSBs repair in higher eukaryotes. 
 
Figure 2. DNA-repair pathways. Different mechanisms repair the high number of structurally distinct 
DNA lesions (adapted from Hakem 2008). 
 
 
In the past decade the interest in the DDR field has enormously increased. On one side it is 
evident that, in exercise of its role as “guardian” of the genome, DDR represents an essential 
anticancer barrier (Bartkova et al., 2005; Gorgoulis et al., 2005). Indeed, defects in DDR 
components impair genomic integrity and create a permissive environment for cancer 
evolution. Conversely, DNA damaging agents are widely used in anticancer therapy. Tumour 
cells are often characterized by genomic instability and high proliferative rates, and are 
therefore preferential targets of DNA damaging agents with respect to normal cells. However, 
activation of DDR in cancer cells might reduce the effectiveness of DNA damaging therapies 
and result in resistance to treatment (Zhou and Bartek, 2004). The selective inhibition of DDR 
in tumour cells could therefore sensitize them to DNA damaging agents (chemosensitization). 
Moreover, current advances show that specific defects in DDR often occurring in cancer cells 
are synthetically lethal with the inhibition of complementary repair pathways and can 
therefore be exploited for cancer therapy (Reinhardt et al., 2009).  
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For these reasons, a great effort has been devoted to understand the signal-transduction 
pathways that mediate response to DNA damaging agents in normal and cancer cells. 
 
 
Organization of the DNA damage response: the ATR-Chk1 and ATM-Chk2 pathways 
 
The DDR is a multifaceted pathway that promptly adapts to the nature of DNA damage and to 
the stage of the cell cycle in which the lesion occurs. Indeed, the same DNA insult can 
activate different DDR pathways in different cell type contexts. The various DDR 
mechanisms have a common general organization (Figure 3) (Jackson and Bartek, 2009), but 
it is important to underlie that all the components of DDR are highly interconnected and 
reciprocally regulated. At least in the first phases, the regulation of cellular response to DNA 
damage strongly depends on post-translational modifications of proteins, which provide a 
rapid and reversible way to modulate protein-protein interactions and regulate protein 
trafficking, activity and stability (Huen and Chen, 2008). 
 
 
Figure 3. Conceptual organization of the DDR. DNA lesions are recognized by sensor proteins that, 
through specific mediators, transmit the signal to transducer and effector components. Many of the transducer 
and effector proteins promote post-translational modifications of their targets in order to activate the appropriate 
cellular responses (adapted from Jackson 2009). 
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At the core of DDR there are the transducer kinases ATR (ataxia telangiectasia and Rad3 
related) and ATM (ataxia telangiectasia mutated) and their substrates checkpoint kinase 1 
(Chk1) and 2 (Chk2) (Figure 4) (Shiloh, 2003; Smith et al.). 
ATM and ATR are large serine/threonine kinases which belong to the phosphatidylinositol-3-
kinase (PI3K) family, but which act only on proteic substrates (Abraham, 2001).  
ATM was identified in 1995 as the product of the gene mutated in the autosomal recessive 
syndrome ataxia telangiectasia (A-T), a genomic instability disorder. ATM is present in 
undamaged cells as an inactive homodimer (Bakkenist and Kastan, 2003). Following DSBs 
formation, ATM is rapidly recruited to damage sites by association with the sensor complex 
MRN [MRE11 (meiotic recombination 11)-RAD50-NBS1 (Nijmegen breakage syndrome 1)] 
(Lee and Paull, 2005) and autophosphorylates at S1981, S367 and S1893 residues (Kozlov et 
al., 2006), leading to dissociation of the homodimer in active monomers. 
Unlike ATM, ATR is predominantly activated by single strand DNA (ssDNA) tracts 
(Cimprich and Cortez, 2008) that are generated when DNA replication is impeded - for 
example following UV light exposure, or as a consequence of nucleolytic strand resection 
during HR repair (Jazayeri et al., 2006). ssDNA tracts are rapidly coated with a trimeric 
complex, called Replication Protein A (RPA), which recruits ATR via its partner ATRIP (Zou 
and Elledge, 2003). ATR activation is not dependent on post-translational modifications of 
the kinase, but depends on recruitment of two mediator proteins, TopBP1 (Delacroix et al., 
2007) and Claspin (Freire et al., 2006). 
In a recent screening, hundreds of potential substrates of ATM and ATR kinases have been 
identified (Matsuoka et al., 2007). ATM/ATR signalling pathways enhance repair by 
recruiting, activating and inducing repair factors. In parallel, they activate cell cycle 
checkpoints, which slow down or arrest the cycle in order to allow the cell to repair the 
damaged DNA before progression to the next phase. Progression through the cell cycle is 
regulated by Cyclin-CDK (Cyclin-dependent-kinases) complexes. Although distinct Cyclin-
CDK complexes act in the different phases of the cycle, they are regulated by a common 
mechanism in which phosphorylation of CDKs negatively affects the activity of the complex. 
These phosphorylation events are counteracted by the activity of Cdc25 phosphatase family. 
Following DNA damage, ATM and ATR phosphorylate the kinases Chk2 and Chk1 
respectively (Smith et al., 2010). In turn, activated Chk2 and Chk1 phophorylate Cdc25s and 
target them to proteosomal degradation, thereby enhancing CDKs phosphorylation and 
inhibiting cell cycle progression (Smith et al., 2010). Chk1, which is predominantly expressed 
in S and G2 phases in proliferating cells (Kaneko et al., 1999), is activated by ATR by a broad 
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spectrum of DNA damaging agents and mainly regulates S and G2-M checkpoints. Chk2 is 
activated primarily by ATM in response to DSBs, although phosphorylation by ATR and 
DNA-PK can also occur (Hirao et al., 2002; Li and Stern, 2005; Matsuoka et al., 2000). Chk2 
seems to play a partially redundant and supportive role in checkpoints control, while it seems 
to be more important for regulation of apoptosis upon DNA damage (Stracker et al., 2009; 
Zhou and Bartek, 2004). However, it is important to underline that ATR-Chk1 and ATM-
Chk2 pathways are significantly interconnected and that among the wide number of Chk1 and 
Chk2 substrates, many are common to ATM and ATR (Stracker et al., 2009). 
 
 
Figure 4. The ATM-Chk2 and ATR-Chk1 pathways in DDR. Upon DNA damage, the activation 
of the kinases ATM, ATR and of their substrates Chk2 and Chk2 promotes the adaptative response of the cell 
(adapted from Zhou and Bartek, 2004). 
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Che-1, a newly identified player in DNA damage response 
 
The human gene AATF (apoptosis antagonizing transcription factor) encodes for a 558 amino 
acids protein, commonly referred as Che-1, which is highly conserved among eukaryotes. 
Che-1 amino acidic sequence harbours two highly acidic regions at the amino-terminal, a 
central leucine zipper motif and three LXXLL receptor interaction motifs distributed 
throughout the protein (Passananti et al., 2007). Che-1 is predominantly a nucleolar protein 
(Andersen et al., 2005), but a cytosolic localization has been observed in neuronal cells 
(Barbato et al., 2003).  
The first evidences regarding Che-1 function highlighted its strong anti-apoptotic activity 
(Figure 5). Page et al. (1999) demonstrated that Che-1 interacts with DAP-like kinase (DLK), 
a pro-apoptotic serine-threonine kinase, and antagonizes its function. In neural tissues Che-1 
inhibits apoptosis induced by Par-4, a pro-apoptotic protein involved in aberrant production of 
?-amyloid peptide in Alzheimer’s disease (Guo and Xie, 2004), and protects neuronal cells 
from ?-amyloid induced cell death (Xie and Guo, 2004). Furthermore, execution of the 
apoptotic programme requires Che-1 degradation, which is regulated by the prolyl isomerase 
Pin1 (De Nicola et al., 2007) and, in neuronal cells, by the neutrophin receptor-interacting 
MAGE homolog NRAGE (Di Certo et al., 2007). Both proteins promote Che-1 ubiquitination 
and its proteasome-mediated degradation. 
Moreover, Che-1 has an established role as transcriptional activator (Page et al., 1999) , and 
its expression is essential during early stages of embryogenesis (Thomas et al., 2000). 
Although it does not directly bind DNA, Che-1 acts as a mediator which links the general 
transcription apparatus with different transcription factors, promoting the expression of target 
genes (Passananti et al., 2007). Che-1 amino acidic sequence shares some fragments of 
similarity with SV40 early gene large T antigen and with Escherichia coli ?-factor 70. 
Furthermore, Che-1 was identified as a binding partner of RBP11, the core subunit of human 
DNA Polymerase II which, together with RPB3, is the functional counterpart of the ? subunit 
homodimer in Escherichia coli (Fanciulli et al., 2000). Che-1 has been shown to enhance 
transactivation activity of several steroid-receptors and to interact with the tumour suppressor 
TSG101, cooperatively stimulating androgen receptor-mediated transcription (Burgdorf et al., 
2004). 
Che-1 transactivation activity is pivotal in many steps of cell-cycle regulation (Figure 5). 
Several experiments indicate that Che-1 acts as a general HDAC1 competitor in different cell 
contests. At the G1/S transition, Che1 was found to interact with the retinoblastoma (Rb) 
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protein and to promote cellular proliferation (Bruno et al., 2002). During G1 phase Rb 
interacts with the transcription factor E2F1 and recruits class I histone deacetylase proteins 
(HDACs) onto E2F1 target promoters, repressing the transcription of the corresponding 
genes. At the G1/S transition an increase in Che-1 protein levels, probably due to 
hyperphosphorylation of the protein, leads to a higher amount of Che-1-Rb complexes. This 
interaction displaces HDAC1 from the Rb-E2F1 complexes at the target promoters and 
relieves the inhibitory effect on transcription, stimulating therefore G1/S transition and cell 
proliferation. On the other side, overexpression of Che-1 in human colon carcinoma cells 
inhibits cell proliferation by activating the expression of the cyclin-dependent kinase inhibitor 
p21 (Di Padova et al., 2003). Che-1 can bind the transcription factor Sp1 and displace 
HDAC1 from its target sites in p21 promoter. In line with these evidences, Che-1 has been 
found downregulated in several tumours, including colon and kidney carcinoma. 
 
Figure 5. Multiple roles of Che-1 in cell-cycle and apoptosis regulation. See the text for 
details (adapted from Passananti et al., 2007). 
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Recently, a role of Che-1 in DDR signalling has been evidenced (Bruno et al., 2006). In 
response to DNA damaging agents the kinases ATM, Chk2 and, to a less characterized extent, 
ATR and Chk1 phosphorylate Che-1 at four serine residues (Ser187 by ATM; Ser141, Ser474 
and Ser508 by Chk2). This post-translational modification prevents Che-1 degradation by the 
proteasome and promotes its stabilization and accumulation. Moreover, phosphorylated Che-1 
is recruited on the TP53 and p21 promoters and activates the expression of the corresponding 
genes, contributing to the maintenance of the G2/M checkpoint in a p53-dependent way. 
Failure to maintain the G2/M checkpoint in Che-1 silenced cells leads to an increase in 
apoptosis and therefore in sensitivity to DNA damaging agents; notably, this effect is specific 
for cancer respect to normal cells. These observations prompted the authors to suggest Che-1 
depletion as a therapeutic means to specifically sensitize tumour cells to anticancer agents 
(chemosensitization, see above). In line with these findings, in a recent work the same authors 
demonstrated that Che-1 sustains mutant p53 expression in several tumour cell lines, and that 
silencing of Che-1 induces apoptotic cell death (Bruno et al., 2010). 
 
 
Poly(ADP-ribosyl)ation reactions 
 
ADP-ribosyl)ation is a post-translational modification of proteins which consists in the 
transfer of ADP-ribose units from nicotinamide adenine dinucleotide (NAD
+
) to glutamic 
acid, aspartic acid and lysine residues of acceptor proteins (Figure 6) (Freire et al., 2006). The 
ADP-ribose units can be linked via glycosidic ribose-ribose bonds forming highly negatively 
charged ADP-ribose polymers (PAR) containing 2-200 units, which can be linear or 
irregularly branched every 20-50 units. Beyond this covalent modification, a so called “non-
covalent” modification has been extensively characterized. Indeed, PAR can interact with a 
number of target proteins which harbour specific PAR-binding consensus motifs. So far, three 
different PAR-interaction motifs have been identified: a 20 aminoacid consensus sequence 
rich in basic residues (Pleschke et al., 2000), a C2H2 zinc-finger referred as PBZ (Ahel et al., 
2008) and a macrodomain structure (Ahel et al., 2009; Gottschalk et al., 2009; Timinszky et 
al., 2009). These interaction sequences often overlap with functional domains of target 
proteins, whose activity can therefore be modulated by binding to PAR. Although non-
covalent, the interaction between PAR and the target protein results to be very strong and 
resists phenol partitioning, strong acids, detergents and high salt concentrations (Panzeter et 
al., 1992). Recently, a proteomic analysis of PAR binding proteins has revealed a wide 
 13 
number of PAR-interacting proteins (Gagne et al., 2008). At the present, 22 human proteins 
that possess an ADP-ribosyltransferase catalytic domain have been identified . These enzymes 
are historically referred as poly(ADP-ribose) polymerases (PARPs), although they effectively 
catalyze a transferase  reaction and not a template-dependent polymerase reaction. Moreover, 
only two members of the family have a confirmed poly(ADP-ribosyl)transferase activity 
(PARP-1 and PARP-2) and can synthetize PAR on themselves (automodification) or on target 
proteins (heteromodification). Therefore a new unified nomenclature for this family has been 
recently proposed (Hottiger et al.).  
Poly(ADP-ribose) polymerase-1 (PARP-1 or, according to the new nomenclature, ARTD1) is 
the founding member of the PARP family and is the main enzyme responsible for PAR 
production in the cell. It is an abundant and highly conserved nuclear protein of 116 kDa that  
 
 
 
 
 
Figure 6. Catabolism and anabolism 
of PAR. The structure of a branched PAR is 
shown, such as the enzymatic actions of PARP, 
PARG and of the (ADP-ribosyl) protein lyase 
which removes the first monomer bound to the 
target protein. 
NAD
+
, the substrate of PARP catalytic activity, 
can be synthetized from nicotinamide through 
the action of the enzymes nicotinamide 
phosphoribosyl transferase (NAMPT) and 
nicotinamide mononucleotide 
adenylyltransferase (NMNAT). Additional 
pathways of NAD
+
 production (Schreiber 2006) 
are not reported.  
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is ubiquitously expressed (Krishnakumar and Kraus).  PARP-1 has a modular structure 
composed by: 
• an amino-terminal DNA-binding domain (DBD), which contains two zinc-fingers that 
mediate binding to DNA and a third zinc-finger important for DNA-dependent 
activation of the enzyme (Langelier et al., 2008). The nuclear localization signal and a 
capsase-3 cleavage site are also present in this domain; 
• a central automodification domain (AD), which harbours PAR acceptor residues 
(Altmeyer et al., 2009) (Tao et al., 2009) and a BRCT fold (BRCA1 carboxy-terminal 
domain) which mediates protein-protein interactions and which is found in many DDR 
components; 
• a carboxy-terminal catalytic domain (CD) which contains a highly conserved PARP 
signature motif for NAD
+
 binding and a WGR (Trp, Gly, Arg) motif with unknown 
function. 
 
 
 
Figure 7. Structure of PARP-1. A schematic representation of human PARP-1. FI, FII and FIII: zinc-
finger domains; NLS: nuclear localization signal; BRCT, BRCA1 carboxy-terminal domain; WGR: WGR (Trp, 
Gly, Arg) motif; the PARP signature motif a the C-terminal of the protein is indicated in red (adapted from 
Krishnakumar 2010). 
 
 
PARP-1 in DNA damage response 
 
PARP-1 is involved in a wide range of cellular processes, which include chromatin structure 
and transcription, cellular signalling, regulation of cell-cycle and mitosis. However, the 
earliest and most characterized functions of PARP-1 are related to DNA repair and 
maintenance of genomic stability. Indeed, although viable, parp-1 knock-out mice show 
hyper-sensitivity to genotoxic stresses (Tong et al., 2001). Although to a lesser extent than 
PARP-1, also PARP-2 is activated following DNA damage, and can therefore have a 
compensatory effect in parp-1 knock-out models. According to this, parp-1/parp-2 double 
knock-out mice die early during embryogenesis.    
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PARP-1 is a molecular sensor of both SSBs and DSBs generated by a variety of DNA 
damaging agents (D'Amours et al., 1999). PARP-1 binds as a dimer to these structures 
(Mendoza-Alvarez and Alvarez-Gonzalez, 1993) and its catalytic activity is stimulated up to 
500 fold  (Simonin et al., 1993) leading to intermolecular automodification of the enzyme or 
to heteromodification of target proteins. Automodification of PARP-1 upon DNA damage 
consists in the addition of PAR of heterogeneous length spanning from few to around 200 
units (D'Amours et al., 1999). According to the “PARP shuttling” model (Figure 8), the 
progressive addition of negative charges during PARP-1 automodification gradually decreases 
the affinity of the enzyme for DNA up to a repulsion point in which PARP-1 dissociates from 
DNA and its catalytic activity is inactivated. PARP-1 release allows the acces of repair factors 
 
Figure 8.  Shuttle model of 
PARP-1.  PARP-1 is activated 
upon recognition of DNA breaks. 
Automodification of PARP-1 
increases the negative charge of 
the protein and reduces the 
affinity of the enzyme for DNA. 
When the electrostatic repulsion 
point is reached, the enzyme is 
released form DNA and its 
activity is inhibited. Reactivation 
of PARP-1 requires degradation 
of PAR by the PARG enzyme 
(adapted from D’Amours et al., 
1999).  
 
 
 
to DNA. The activity of poly(ADP-ribose) glycohydrolase (PARG), the enzyme which 
degrades PAR, guarantees the reactivation of PARP and the dynamic of this process. 
The functional consequences of PARP activation depend on the extent of DNA damage. A 
transitory activation of PARP upon mild damage promotes the activation of repair and cell-
survival pathways. Over-activation of PARP-1 caused by severe DNA damage leads to 
NAD+ and ATP depletion, and therefore to necrotic cell death. Contrariwise during apoptosis 
in order to avoid consumption of the ATP levels necessary for the execution of apoptotic 
program PARP-1 is inactivated through cleavage by caspase-3. Alternatively PARP-1 activity 
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induces translocation of the apoptosis-inducing factor (AIF) from the mitochondria to the 
nucleus, resulting in a caspase-independent cell death (Cregan et al., 2002).  
The local production of PAR at the DNA damage has a pivotal role in recruiting repair factors 
to DNA damage sites (Figure 9). For example, the scaffold protein XRCC1, which is 
necessary for the activation of BER machinery (El-Khamisy et al., 2003), harbours a PAR 
interaction motif and its recruitment to DNA lesions is affected by PARP inhibition (Okano et 
al., 2003). Similarly, other repair proteins, such as DNA ligase III (Leppard et al., 2003), 
proliferating cell nuclear antigen (PCNA) and the p150 subunit of chromatin assembly factor 
 
 
Figure 9. Roles of PARP-1 
in DDR. PAR production at the 
DNA damage sites represents a 
unique signal that mediates 
chromatin remodelling, 
recruitment of repair factors and 
coordinates the transduction 
cascade which allows the cell to 
respond according to the severity 
of the injury.   
 
1 are recruited at DNA repair foci in a PAR-dependent way. At the same time both 
poly(ADP-ribosyl)ation of histones H1 and H2B and their non-covalent interaction with PAR 
lead to relaxation of chromatin, facilitating the access of the repair factors to DNA breaks.  
In the recent years it has appeared clear that PARP-1 activity is also involved in the 
transduction of the signal induced by DNA damage, coordinating the local detection of DNA 
breaks with downstream cell responses.  Many important checkpoint proteins, such as p21 and 
p53, harbours a PAR binding motif (Ahel et al., 2009; Pleschke et al., 2000). The PAR-
binding domain of p53 overlaps with its DNA binding domain (Malanga et al., 1998) and can 
therefore modulate the interaction with target sequences. Moreover, p53 can be covalently 
poly(ADP-ribosyl)ated by PARP-1, and this modification has been shown to be necessary for 
p53 nuclear accumulation upon DNA damage. Inhibition of PARP activity attenuates 
transcription of p21 (Madison and Lundblad, 2010; Wieler et al., 2003)  and of the repair 
genes BRCA1 and RAD51 (Hegan et al., 2010). Further on, poly(ADP-ribosyl)ation of PARP-
1 has been recently reported to promote the assembly of a signalosome complex that 
ultimately leads to NF-kB activation in response to ionizing radiation (Stilmann et al., 2009). 
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The role of PAR signalling in regulating the phosphorylation cascade initiated by the ataxia 
telangiectasia mutated (ATM) kinase has also been investigated. Despite initial conflicting 
results (Goodarzi and Lees-Miller, 2004; Watanabe et al., 2004), an association between 
ATM and PARP-1 in response to ionizing radiation has been described (Aguilar-Quesada et 
al., 2007) and recently ATM has been added to the list of PAR-binding proteins (Gagne et al., 
2008; Haince et al., 2007). In particular, Poirier and coworkers (Haince et al., 2007) 
demonstrated that in the early phases of DNA damage induced by N-methyl-N’-nitro-N-
nitrosoguanidine (MNNG) PAR synthesis at DSBs is necessary to recruit ATM and induce 
the downstream response to damage, i.e. the phosphorylation of ATM targets such as p53.
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AIM OF THE THESIS 
 
 
Although phosphorylation reactions play a 
pivotal role in coordinating DDR, other post-
translational modifications are involved in this 
complex pathway. Among these, poly(ADP-
ribosyl)ation has been shown to be important not 
only in sensing DNA damage and recruiting 
repair factors, but also in regulating the signal 
transduction in DDR. In particular, the finding 
that PARP-1 can modulate ATM-mediated 
network prompted us to analyze the role of 
poly(ADP-ribosyl)ation in the regulation of Che-
1 levels, a newly identified ATM target which is 
stabilized following phosphorylation by DDR 
kinases (Figure 10). 
 
 
 
 
 
         Figure 10. Aim of the thesis 
 
We used as experimental models human colon carcinoma HCT116 cells and mouse 
embryonic fibroblasts derived from PARP-1
+/+ 
and PARP-1
-/-
 mice. To induce DNA damage, 
cells were treated with doxorubicin (Doxo), an anthracycline antibiotic commonly used in 
chemotherapy. Doxo is a topoisomease II inhibitor that interferes with the religation step and 
leads to stabilization of the enzyme-DNA complex, eventually generating DSBs. Doxo 
treatment has been shown to induce stabilization of Che-1 through the activation of  ATM-
Chk2 and ATR-Chk1 pathways (Bruno et al., 2006).  
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EXPERIMENTAL PROCEDURES 
 
Cell cultures and drug treatment 
 
Human colon carcinoma HCT116 cells and MEF derived from PARP-1
+/+ 
and PARP-1
-/-
 mice 
(Wang et al., 1995) were grown in high glucose (4,5 g/litre) Dulbecco’s modified Eagle's 
medium supplemented with 10% foetal bovine serum. SV40-transformed normal skin 
fibroblasts (GM00637) and ataxia-telangiectasia (A-T) fibroblasts (GM09607) were obtained 
from the Coriell Institute and grown in modified Eagle's medium supplemented with 10% 
foetal bovine serum. All culture solutions were purchased from International PBI and 
supplemented with 2 mM L-glutamine and 50 units/ml Penicillin-Streptomycin. 
Cells were grown to about 70% confluence and when indicated were treated with doxorubicin 
(Sigma, final concentration 1 μM), 3-aminobenzamide (Sigma, final concentration 8 mM), 
PJ-34 (Alexis, final concentration 5 μM), KU55933 (Sigma, final concentration 10 μM). 
 
Antibodies 
 
The following mouse monoclonal antibodies were used: anti-PARP-1 (clone C2-10; Alexis), 
anti-PARP-1 (clone F1-23; Alexis), anti-PAR (clone 10HA; Trevigen), anti ?-actin (clone 
AC-15; Sigma); anti-Myc (9E10 clone, hybridoma-conditioned medium); anti-P-histone 
H2AX (Upstate). Rabbit polyclonal antibodies used were anti-PARP-1 (Alexis) and anti-Che-
1 (Fanciulli et al., 2000). 
 
Western blotting  
 
Total cell extracts were obtained by lysis in RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 1 mM EDTA, 100 mM NaF, 3 mM Na orthovanadate, 10% glycerol, 1% NP-40) 
supplemented with protease inhibitors (complete EDTA-free, Roche Applied Science). 
Lysates were kept on ice for 20 min and then centrifuged at 16000 g for 20 min at 4°C. 
Supernatants were collected and quantified by Bradford protein assay reagent (Bio-Rad). 
Equal protein amounts were separated by SDS-PAGE and electroblotted onto nitrocellulose 
membrane (Hybond
TM
 ECL
TM
 GE Healthcare). Immunoblots probed with the specific 
antibodies were developed using ECL or ECL-PLUS chemioluminescence reaction (GE 
Healthcare). 
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Extraction of nucleic acids and qRT-PCR 
 
Total RNA was purified by RNeasy mini kit (Qiagen) and genomic DNA was digested by 
RNase-free DNase (Qiagen) treatment. RNA concentration and quality were evaluated by 
spectrophotometer analysis and agarose gel electrophoresis. 
Total RNA (2 ?g) was subjected to retrotranscription using Superscript First-Strand Synthesis 
system (Invitrogen). Expression of Che-1 mRNA was measured by real time PCR using 
iCycler IQ detection system (Bio-Rad). In mouse cells, a Taq-Man gene expression assay 
(Applied Biosystems) was used and relative Che-1 expression was normalized with respect to 
hypoxanthine-guanine phosphoribosyltransferase (Hprt-1) expression. Human CHE-1 and 
p21 expressions were analyzed using SYBR Green Supermix (Bio-Rad) and normalized to 
HPRT-1 expression. TaqMan gene expression assay IDs for each set of primers and probe 
were: Che-1, Mm00498160_m1; Hprt1, Mm00446968_m1. The sequences of the primer used 
in SYBR Green assay were: CHE-1 forward, GCTGCTGAGGAACAGGAGTGT; CHE-1 
reverse, ACTGAAGCCCGGTGTTTTTG; p21 forward, AGACCAGCATGACAGATTTC; 
p21 reverse, ACTGAGACTAAGGCAGAAGA;  HPRT-1 forward, 
TTGGAAAGGGTGTTTATTCCTCA; HPRT-1 reverse, TCCAGCAGGTCAGCAAAGAA. 
To evaluate the PCR efficiency for each set of primers, a standard curve was generated using 
serial dilutions (from 50 to 6.5 ng) of cDNA obtained from control cells. The efficiency was 
90–100% for all the primers used. The amplification reaction was performed in duplicate for 
each sample in 96-well plates. The amount of Che-1 mRNA was calculated adopting the 
delta-delta-Ct method.  
 
Chromatin Immunoprecipitation (ChIP) 
  
ChIP experiments were performed as previously described (Zampieri et al., 2009). 
Immunoprecipitation with normal rabbit total IgG was performed as negative control. PCR 
amplification was performed using the following  p21 promoter-specific primers (Bruno et al., 
2006): forward, TCCGGGACCGGCTGGCCT; reverse, GCTCGGCCCACCGCGCCG. 
Reaction conditions were tested for signal linearity using increasing amounts of  DNA 
template. 
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Immunofluorescence and Confocal Laser Scanner Microscopy 
 
Cells were seeded onto sterile glass coverslips. After 3 days, cells were treated with the 
indicated drugs and washed twice with PBS. For PAR immunofluorescence cells were fixed 
in 2% formaldehyde and permeabilized with 0.25% Triton X-100 for 5 min at room 
temperature. For PARP-1 and Che-1 double immunofluorescence, cells were fixed in 
methanol:aceton (1:1 v/v) for 10 min at 4°C, dried, washed with PBS with 0.1% Tween 20 
and blocked with 3% PBS-BSA for 30 min at room temperature. In both cases, coverslips 
were incubated at 4°C overnight with the specific antibodies (anti-PAR: clone 10HA, 
Trevigen; anti-PARP: clone F1-23, Alexis; anti-Che: rabbit polyclonal) and, after extensive 
washes with PBS, stained for 1 hr at room temperature with fluorescein-conjugate donkey 
anti-mouse and rhodamine-conjugated donkey anti-rabbit secondary antibodies (Jackson 
ImmunoResearch). After extensive washing with PBS, coverslips were mounted on 
microscope slides with glycerol/PBS (pH 9). Samples were analyzed using a Leica confocal 
laser scanning microscope (Laser Scanning TCS SP2) equipped with Ar/ArKr and HeNe 
lasers. Laser line was at 488 nm for excitation FITC and 543 for excitation TRITC. The 
images were scanned under a 40 oil immersion objective. Optical spatial series were 
performed with a step size of 1 μm.  
 
Transfections 
 
For PARP-1 silencing, cells were transfected with siRNA (Dharmacon) at a final 
concentration of 50 nM using INTERFERin
TM
 transfection reagent (Polyplus Transfection) 
following manufacturer's instructions. Overexpressions of empty Myc vector and Myc-Che-1 
vector were carried out using jetPEI
TM
 transfection reagent (Polyplus Transfection) following 
manufacturer's instructions. 
 
Recombinant proteins and GST-pulldown assay 
 
BL21 E. coli strain was transformed with pGEX4T3 vector (Pharmacia) or GST-Che-1 vector 
[25] and the proteins were purified on glutathione-Sepharose resin
 
(GE Healthcare). For GST-
pulldown assay,
 
comparable amounts of resin-bound GST-tagged proteins were incubated
 
with high purity human recombinant PARP-1 (Alexis) or PARP-1 automodification domain 
(AD) (Alexis) in NETN buffer (20 mM Tris-HCl,
 
pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% 
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Nonidet P-40) for 2 hrs at 4°C. For GST-pulldown with automodified PARP-1, 500 ng of 
recombinant PARP-1 were previously incubated for 2 hrs at 30°C in poly(ADP-ribosyl)ation 
buffer (50 mM Tris-HCl, pH 8.0, 10 mM MgCl2, 1 mM DTT) containing 0.1 μg of DNase I-
activated DNA (Alexis) and 400 ?M NAD. After incubation the resins were pelleted and 
extensively
 
washed in NETN buffer. The bound proteins were resuspended in SDS sample 
buffer and analyzed
 
by 8% SDS-PAGE and Western blotting.  
 
Immunoprecipitation 
 
For Che-1 co-immunoprecipitation, nuclei were isolated from HCT116 cells in RSB buffer 
(10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT, 50 mM NaF) and lysed 
in buffer containing 20 mM HEPES, pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 
0.5 mM DTT, 25% glycerol. Nuclear extracts were diluited 1:3 in immunoprecipitation buffer 
(50 mM Tris-HCl, pH 7.4, 50 mM NaCl, 5 mM EDTA, 10 mM NaF, 0.2% NP40) and 
precleared with protein A-agarose beads (Upstate) on a rotative shaker at 4 °C for 2 hrs. Pre-
cleared lysates were incubated overnight at 4°C with anti-Che-1 antibody or with normal 
rabbit IgG (Santa Cruz Biotechnology) and then incubated 2 hrs at 4°C with protein A-
agarose beads. After extensive washing, immunoprecipitates were subjected to 8% SDS-
PAGE and Western blotting. For PAR immunoprecipitation, cell were directly collected in 
lysis buffer (175 mM KPO4, pH 8.0, 1% NP40, 150 mM NaCl, 1 mM DTT, 100 μM 
ethacridine, protease inhibitors), mixed by inversion 1 hr at 4°C and centrifugated 10 min at 
6000 g at 4°C. NP40 concentration was adjusted to 0.5% and cell extracts were pre-cleared, 
incubated 2 hrs at 4°C with anti-PAR antibody or normal mouse IgG (Santa Cruz 
Biotechnology) and 2 hrs at 4°C with protein G-agarose beads (Upstate). Subsequently, beads 
were washed in 0.5% NP40 lysis buffer and analyzed by 8% SDS-PAGE and Western 
blotting. To detect in vivo poly(ADP-ribosyl)ation of Che-1, the buffer for PAR 
immunoprecipitation was modified to achieve 1% NP40 and 1 M NaCl concentrations. Anti-
Myc immunoprecipitation was carried out as described above for PAR immunoprecipitation, 
but using a buffer containing 175 mM KPO4, pH 8.0, 1% NP40, 400 mM NaCl, 1 mM DTT, 
100 μM ethacridine, protease inhibitors.  
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Polymer blot assay 
 
PAR were purified from PARP-1 automodified in vitro [27] in non-radioactive conditions. 
Polymer blot was performed as described [28]. Briefly, increasing amounts (5, 10 and 15 
pmol) of GST, GST-Che-1, histone H1 (positive control) and DNase I (negative control) were 
dotted onto nitrocellulose membrane (Hybond
TM
 ECL
TM
 GE Healthcare) using a dot blot 
apparatus (BioRad). The membrane was blocked overnight in 5% nonfat dry milk in Tris-
buffered saline (TBS, 10 mM Tris, 0.15 M NaCl, pH 7.4) plus 0.05% Tween 20 (TBST), 
washed and then incubated with 2 μg of PAR diluted in 3 ml of TBST. The membrane was 
extensively washed with TBST containing 0.5 M NaCl and subjected to immunodetection 
with anti-PAR antibody. 
 
In vitro poly(ADP-ribosyl)ation of recombinant Che-1 
 
The GST moiety was cleaved from recombinant GST-Che-1 by overnight incubation with 
thrombin (GE Healthcare). 1.0 μg of recombinant Che-1 was pre-incubated 20 min at room 
temperature with high purity recombinant PARP-1 (0.1 μg; Alexis) in reaction buffer (final 
volume 25 μl) containing 50 mM Tris-HCl, pH 8.0, 5 mM MgCl2 and 1 mM DTT. In the 
indicated sample 8 mM 3-ABA was added, and in all samples 0.15 μg of DNase I treated 
DNA and 100 μM NAD+ were added. The incubation was carried out for 20 and 30 min at 
30°C. The reaction was terminated by addition of SDS sample buffer and boiling of the 
samples. Proteins were separated by 8% SDS-PAGE and subjected to anti-PAR and anti-Che-
1 immunodetection. 
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RESULTS 
 
 
Effect of doxorubicin treatment on PARP activity 
 
To evaluate PARP response induced by Doxo, PARP activity was measured by 
immunofluorescence and immunoblotting analysis. Human colon carcinoma HCT116 cells 
were treated with Doxo 1 μM for 4 hrs and PARP activity was evaluated by indirect 
immunofluorescence against PAR. A significant increase in PAR level was observed in the 
nuclei of Doxo treated cells with respect to control cells (Figure 11A). HCT116 cells were 
then treated with Doxo at different times up to 8 hrs. At the indicated times this Doxo 
concentration produced a non-apoptotic damage as previously evidenced by FACS analysis 
showing a sub-G1 peak less than 8% (De Nicola et al., 2007). Immunoblotting analysis 
showed a clear increase in PAR level detectable as early as 30 min after the treatment and 
which persisted up until 8 hrs in the presence of the drug (Figure 11B). As expected, Doxo 
treatment caused an increase in Che-1 protein level in a time-dependent manner (Figure 11B) 
due to Che-1 stabilization (Bruno et al., 2006). PARP-1 did not exhibit any cleavage, 
consistent with the exposure of the cells to a non-apoptotic damage. 
 
Figure 11. Effect of 
Doxo treatment on 
PAR synthesis. (A) 
Immunofluorescence analysis 
of PAR level in HCT116 
control cells and after 4 hrs of  
1 μM Doxo treatment. Nuclei 
are visible in bright field 
images. Overlaid images 
show that Doxo induces PAR 
formation in nuclei. (B) Time 
course of PAR formation in 
HCT116 cells after 1 μM 
Doxo treatment. Western 
blotting was performed on 
total cell extracts using the 
indicated antibodies. 
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PARP-1 activity is required for efficient Che-1 accumulation in doxorubicin treated cells  
 
The role of poly(ADP-ribosyl)ation in the process leading to Che-1 accumulation was 
investigated using two different  PARP inhibitors: 3-aminobenzamide (3-ABA) and PJ-34. 
HCT116 cells were pre-treated with 8 mM 3-ABA 30 min before Doxo treatment and the 
inhibitor was maintained in the medium during the course of the damage (4 hrs). Treatment of 
cells with 3-ABA (Figure 12A) caused a clear inhibition of PAR synthesis both in Doxo-
untreated and Doxo-treated cells. Notably, we observed a significant reduction of Che-1 
accumulation in cells co-treated with 3-ABA and Doxo with respect to cells treated with 
Doxo alone (Figure 12A, B). According to Haince et al. (2007), PARP activity inhibition also 
decreased phosphorylation of the ATM substrate H2AX (Figure 12A). 
 
 
Figure 12. PARP inhibitors affect Che-1 stabilization upon Doxo treatment. (A) HCT116 
cells were treated with Doxo for 4 hrs in the presence or absence of 8 mM 3-ABA (30 min pre-treatment) and 
analyzed by Western blotting using antibodies against PAR, PARP-1 (C2-10 clone), Che-1 , ?-H2AX and ?-
actin. (B) HCT116 cells were exposed to 1 μM Doxo for 4 hrs and co-treated with 5 μM PJ-34 as indicated: 4.5 
hrs corresponds to a 30 min pre-treatment with the inhibitor, while 0.5 hrs indicates that PJ-34 was added in the 
last 30 min of the 4 hrs Doxo treatment. Cell extracts were analyzed by Western blotting using antibodies 
against. (C) and (D) Densitometric analysis of Che-1 signals in three independent experiments performed 
respectively as in (A) and (B). Che-1 protein levels were normalized with ?-actin and indicated as ratio with 
respect to control cells. The asterisks indicate a significant difference (p-value<0.05) in Che-1 levels between the 
compared samples. 
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However, when we performed the same experiment pre-treating the cells with the second 
generation inhibitor PJ-34 (Figure 12C, D), we could not detect a significant impairment in 
Doxo-induced Che-1 accumulation. Conversely, we observed a significant reduction in Che-1 
stabilization when PJ-34 was added in the last 30 min of the 4 hrs Doxo treatment. It is likely  
that prolonged co-treatment (4 hrs) with Doxo and the powerful inhibitor PJ-34 promoted the 
accumulation of unrepaired DNA lesions, and as a consequence did not allow the reduction in 
Che-1 levels which is detectable after shorter exposure to PJ-34 and upon 3-ABA pre-
treatment. 
 Consistent with this, cells exposed to Doxo and PJ-34 for 4 hrs did not exhibited a decrease, 
but a slight increase in phosphorylation of H2AX (Figure 12B). Since our aim was to analyze 
the role of poly(ADP-ribosyl)ation reactions in the first phases of DDR, in the subsequent 
experiments we decided to use 3-ABA as a PARP inhibitor, because it did not induce an 
increase in DNA damage level when used in combination with Doxo. 
PARP-1+/+ and PARP-1-/- mouse embryonic fibroblasts (MEF) (Wang et al., 1995) were 
used to determine whether the absence of PARP-1 could affect Che-1 accumulation during 
Doxo treatment. In a time course of Doxo treatment up to 6 hrs (Figure 13A), an increase in 
PAR level was detectable by immunoblot in PARP-1
+/+
 but not in PARP-1
-/-
 MEF. Notably in 
response to DNA damage, knock-out cells exhibited only a partial increase in Che-1 levels 
with respect to wild type cells (Figure 13A, C). Furthermore, when PARP-1 expression was 
transiently down-regulated by RNA interference in HCT116 cells, we observed a significant 
impairment in Che-1 accumulation following Doxo treatment (Figure 13B, D). 
No alterations in Che-1 mRNA levels were observed following Doxo treatment and in 3-ABA 
inhibited or PARP-1 knock-out cells (Figure 14), confirming a post-translational regulation 
over Che-1 accumulation (Bruno et al., 2006). 
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Figure 13. PARP-1 activity is required for efficient Che-1 accumulation in Doxo treated 
cells. (A) PARP-1+/+ and PARP-1-/- MEF were exposed to 1 μM Doxo for the indicated times and analyzed by 
Western blotting.  (B) HCT116 cells were transfected with control siRNA or PARP-1 specific siRNA, treated 
with 1 μM Doxo for 4 hrs and analyzed by Western blotting. (C) and (D) Densitometric analysis of Che-1 
signals in three independent experiments performed respectively as in (A) and (B). Che-1 protein levels were 
normalized with ?-actin and indicated as ratio with respect to control cells. The asterisk in (D) indicates a 
significant difference (p-value<0.05) in Che-1 levels between the compared samples. 
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Figure 14.  Che-1 mRNA level is not affected by Doxo and 3-ABA treatment. (A) Real-time 
RT-PCR measurements of Che-1 mRNA levels in PARP-1
+/+
 and PARP-1
-/-
 MEF exposed to Doxo for 90 min 
and 4 hrs. The graphs represent Che-1 mRNA levels normalized to Hprt1 mRNA. The mRNA level in untreated 
cells is considered as 1.0. The results are expressed as mean ± S.D. of three independent experiments. (B) Real-
time RT-PCR measurements of CHE-1 mRNA levels in HCT116 cells exposed to Doxo for 4 hrs in presence or 
absence of 3-ABA. The graphs depict CHE-1 mRNA levels normalized to HPRT-1mRNA. 
 
3-aminobenzamide treatment of doxorubicin-exposed HCT116 cells reduces Che-1 
recruitment on p21 promoter and impairs p21 transcription  
 
Che-1 has an established role as a transcriptional activator (Page et al., 1999) and previous 
results showed that upon DNA damage Che-1 physically associates with the p21 promoter 
and stimulates the expression of the corresponding gene (Bruno et al., 2006). Since it has been 
reported that PARP inhibition attenuates p21 expression after IR exposure (Wieler et al., 
2003), we asked whether the reduction in Doxo-induced Che-1 accumulation upon 3-ABA 
treatment could play a role in the modulation of p21 expression. 
As shown in Figure 15A, chromatin immunoprecipitation (ChIP) experiments confirmed Che-
1 recruitment on p21 promoter in Doxo-treated cells. The presence of Che-1 at the p21 
promoter was reduced following pre-treatment of Doxo-exposed cells with 3-ABA and this 
depletion was consistent with an impairment in Che-1 stabilization upon PARP inhibition. 
According to this finding, real-time PCR analysis showed that the increase in p21 expression 
in cells exposed to Doxo was significantly reduced by pre-treatment with 3-ABA (Figure 
15B). 
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Figure 15. Inhibition of PARP activity impairs Che-1 recrutiment on p21 promoter and 
reduces its transcription. (A) HCT116 cells were treated with 1 μM Doxo for 4 hrs with or without 8 mM 
3-ABA (30 min pre-treatment) and subjected to ChIP using anti-Che-1 antibody. Immunoprecipitates from each 
sample were analyzed by PCR using primers specific for p21 promoter. For each sample, amplification was 
performed on total input chromatin (Input) and on ChIP products achieved using normal rabbit IgG as antibody 
(Ctr IgG). (B) Real-time RT-PCR measurements of p21 mRNA levels in HCT116 cells exposed to 1 μM Doxo 
for 4 hrs in presence or absence of 8 mM 3-ABA. The graphs represent p21 mRNA levels normalized to HPRT-1 
mRNA. 
 
 
PARP activity cooperates with ATM kinase activity to stabilize Che-1 
 
PARP-1 has been shown to be important for activation of ATM signalling pathway (Haince et 
al., 2007). Taking into account that Che-1 is an ATM substrate, we performed epistasis 
experiments to investigate whether the effect of PARP activity on Che-1 accumulation was 
mediated by ATM. 
Inhibition of ATM with KU55933 (Figure 16A) reduced Doxo-induced stabilization of Che-1 
in HCT116 cells. The effect of PARP inhibition on Che-1 stabilization was evident also in 
ATM inhibited cells, and an almost complete decrease in Che-1 accumulation was achieved 
when 3-ABA was used in combination with KU55933 (Figure 16A, C).  
We then compared the effects of Doxo and 3-ABA treatments on Che-1 accumulation in 
human fibroblasts ATM-proficient or derived from ataxia teleangiectasia patients (A-T 
fibroblasts) (Figure 16B, D). Although less consistent than in ATM-proficient cells, an 
increase in Che-1 level upon Doxo treatment was evident also in A-T fibroblasts. While in 
ATM proficient fibroblasts 3-ABA caused a reduction in Doxo-induced Che-1 levels 
comparable to that one achieved in HCT116 cells, in A-T fibroblasts it promoted an almost 
complete abrogation of Che-1 stabilization.  
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Overall these results indicate that the effect of poly(ADP-ribosyl)ation on Che-1 stabilization 
is, at least in part, independent of ATM. 
 
 
 
Figure 16. Inhibition of PARP activity impairs Che-1 stabilization in a way independent 
from ATM. (A) HCT116 cells were exposed to 4 hrs 1 μM Doxo treatment after 30 min pre-treatment with 
10 μM KU55933 alone or in combination with 8 mM 3-ABA. Western blotting analysis on cell extracts is 
reported. (B) ATM proficient and A-T fibroblasts were exposed to 1 μM Doxo treatment for 4 hrs in presence or 
absence of 8 mM 3-ABA added 30 min prior to damage. Total cell extracts were analyzed by Western blotting. 
(C) and (D) Densitometric analysis of Che-1 signal in three independent experiments performed as in (A) and 
(B). The signal was normalized with ?-actin and indicated as ratio with respect to control cells. The asterisks 
indicate a significant difference (p-value<0.05) in Che-1 levels between the compared samples.   
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Che-1 co-immunoprecipitates with ADP-ribose polymers but it does not bind them non-
covalently 
 
To further explore the mechanism by which PARP inhibition reduces Che-1 accumulation in 
response to Doxo, we verified whether PAR could directly interact with Che-1 protein.  
HCT116 total cell extracts from control and Doxo-treated cells at 30 and 90 min were 
immunoprecipitated with anti-PAR antibody as indicated in Figure 17A. The PARG inhibitor 
ethacridine (Tavassoli et al., 1985) was used in all the experimental steps to avoid PAR 
degradation. Che-1 co-immunoprecipitated with PAR in control cells and this interaction 
rapidly strengthened upon Doxo-treatment.  
Che-1 aminoacidic sequence does not harbour a consensus motif for non-covalent interaction 
with PAR. However since some proteins, like histone H1, can bind PAR also in absence of a 
canonical PAR-interaction motif, we performed a polymer blot assay. Increasing amounts (5, 
10 and 15 pmol) of GST and GST-Che-1 recombinant proteins were dotted onto the same 
nitrocellulose membrane together with the positive control H1 and the negative control DNase 
I. The filter was incubated with free PAR for 1 hr and PAR bound to proteins were detected 
by anti-PAR antibody. Figure 17 B shows no significant dot blot signal for polymer binding 
to GST and GST-Che-1, whereas histone H1 shows a signal decreasing linearly with the 
amount of protein. These results exclude a non-covalent interaction of Che-1 with PAR, 
pointing to the possible covalent poly(ADP-ribosyl)ation of Che-1. 
 
 
Che-1 interacts with PARP-1 in vivo and in vitro 
 
To test whether PARP-1 was involved in Che-1 accumulation through its direct modification, 
we performed a series of experiments to assess the physical interaction between Che-1 and 
PARP-1. 
We examined the subcellular localization of PARP-1 and Che-1 by immunofluorescence and 
confocal microscopy analysis (Figure 18A). In control cells a strong nucleolar colocalization 
of Che-1 and PARP-1 was observed. Upon exposure of cells to 4 hrs of Doxo treatment, 
delocalization of the two proteins from nucleoli to nucleoplasm occurred. PARP-1 was found 
especially at the periphery of nuclei and Che-1 was mainly distributed throughout the nucleus. 
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Figure 17. Che-1 co-immunoprecipitates with PAR but does not interact with them non-
covalently. (A) Total cell extracts from HCT116 cells untreated or treated with 1 μM Doxo at 30 and 90 min 
were immunoprecipitated with anti-PAR antibody and analyzed by Western blotting with anti-PAR and anti-
Che-1 antibodies. Input corresponds to 5% of the total cellular extract used for immunoprecipitation. Ctr IgG 
indicates immunoprecipitation carried out with control normal mouse IgG. (B) Polymer blot assay to analyze the 
in vitro PAR binding affinity of different proteins. GST, GST-Che-1, histone H1 and DNAase I recombinant 
proteins were spotted onto nitrocellulose membrane in the indicated amount and incubated with free PAR. 
Protein-bound polymers were evidenced using anti-PAR antibody. 
  
 
 
However, we still observed association between Che-1 and PARP-1 after DNA damage, 
evidenced by the persistence of foci of co-localization detected in the merge analysis. 
Co-immunoprecipitation on nuclear extracts with anti-Che-1 antibody confirmed that Che-1 
binds PARP-1 both in HCT116 control and Doxo-treated cells (Figure 18B). This interaction 
appeared to be stimulated upon Doxo treatment, but we could not exclude that this increase 
was caused by the higher level of Che-1 in damaged cells. 
Next GST-pulldown experiments were performed to evaluate whether the observed 
association between PARP-1 and Che-1 was direct. GST and GST-Che-1 were incubated with 
human recombinant PARP-1 (Figure 18C, upper panel) or with the automodification domain 
(AD) of the enzyme (Figure 18C, middle panel). Western blotting analysis showed that GST-
Che-1 specifically binds PARP-1 and in particular that it can interact with its AD. Unless the 
existence of a non-covalent binding, high levels of PAR on the automodification domain  
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Figure 18. Che-1 physically interacts with PARP-1. (A) Nuclear co-localization of PARP-1 and 
Che-1 assessed by immunofluorescence and confocal analyses. Yellow signal in lower panels corresponds to co-
localization of PARP-1 (green signal) and Che-1 (red signal). The optical sections shown are recovered at 
nuclear level. (B) Nuclear extracts from HCT116 cells treated or not with 1 μM Doxo for 4 hrs were 
immunoprecipitated with anti-Che-1 antibody and analyzed by Western blotting with anti-PARP-1 (C2-10 clone) 
and anti-Che-1 antibodies. Input corresponds to 5% of nuclear extract used for immunoprecipitation. Ctr IgG 
indicates immunoprecipitation carried out with control normal rabbit IgG. (C) GST and GST-Che-1 proteins 
were incubated with human recombinant PARP-1 (upper panel), with the automodification domain (AD) of 
PARP-1 (middle panel) or with in vitro automodified PARP-1 (lower panel) and subjected to GST-pulldown. 
The input represents 10% of the total incubate. In Western blotting, full length recombinant PARP-1 was 
detected by the C2-10 monoclonal antibody, AD domain of PARP-1 was detected by anti-PARP-1 polyclonal 
antibody and automodified PARP-1 was detected using anti-PAR antibody.  
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should decrease the interaction between PARP-1 and proteins. GST and GST-Che-1 were 
incubated with recombinant PARP-1 previously automodified in presence of DNase I 
activated DNA and NAD (Figure 17C, lower panel). We used anti-PAR antibody to detect 
automodified PARP-1 as a high molecular smear. As expected, no significant increase in 
signal was detected in the GST-Che-1 pulldown sample with respect to the negative control 
GST (lane 3 vs lane 2).  
Altogether these results indicate that Che-1 directly interacts with PARP-1 and is therefore a 
possible substrate of the catalytic activity of the enzyme. 
 
 
Che-1 is poly(ADP-ribosyl)ated by PARP-1 in vitro and in vivo 
 
We examined whether PARP-1 could modify Che-1 in vitro in a reconstituted poly(ADP-
ribosyl)ating enzyme system. Che-1 was detached from the resin upon overnight cleavage of 
the GST moiety with thrombin. Reaction conditions were optimized for heteromodification. 
Recombinant Che-1 and PARP-1 were pre-incubated for 15 min at room temperature, then 
added of NAD and nicked DNA and incubated at 30°C for 20 and 30 min. The reaction 
products were analyzed by immunoblotting with anti-PAR antibody (Figure 19A). 
Automodification of PARP-1 at 20 and 30 min was detected as a high molecular weight smear 
(lanes 1, 2). In the presence of recombinant Che-1 (lanes 3, 4), the smear started from a lower 
molecular weight which coincided with Che-1 electrophoretic position, as revealed by 
reprobing the filter with anti-Che-1 antibody. No PAR signal was detected when Che-1 and 
PARP-1 were incubated under the same experimental conditions but in presence of 3-ABA 
(lane 5). These results indicate that in vitro Che-1 is a substrate of PARP-1 activity. 
We used different approaches to verify the existence of in vivo poly(ADP-ribosyl)ation of 
Che-1. First of all we immunoprecipitated PAR in highly stringent conditions in order to 
select covalently modified proteins and avoid non-covalent interactions with PAR (Figure 
19B). In these conditions we still observed co-immunoprecipitation of Che-1, indicating a 
covalent poly(ADP-ribosyl)ation of the protein.  
To confirm this data, HCT116 cells were transfected with empty Myc vector or Myc-Che-1 
vector and after 24 hrs were treated with Doxo for 4 hrs. Total cell extracts were 
immunoprecipitated with anti-Myc antibody in stringent conditions (Figure 19C). 
Immunoblot with anti-PAR showed a specific signal overlapping with Myc-Che-1 
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electrophoretic position, confirming the existence of a poly(ADP-ribosyl)ated form of Che-1 
in Doxo-exposed cells. 
 
Figure 19. Che-1 is modified by PARP-1 in vitro and in vivo. (A) In vitro poly(ADP-ribosyl)ation 
of Che-1. Recombinant PARP-1 (0.1 μg) was incubated in poly(ADP-ribosyl)ation buffer for 20 and 30 min 
(lanes 1, 2) alone or in presence of 1.0 μg of recombinant Che-1 (lanes 3, 4). Addition of 3-ABA to the samples 
abolished the modification reaction (lane 5). The reaction mixtures were subjected to 8% SDS-PAGE and 
immunoblotted with anti-PAR antibody (top panel). The membrane was stripped and reprobed with anti-Che-1 
antibody (lower panel). (B) Total cell extracts from HCT116 cells untreated or treated with 1 μM Doxo for 4 hrs 
were immunoprecipitated with anti-PAR antibody in highly stringent conditions (1% NP-40, 1 M NaCl) and 
analyzed by Western blotting with anti-PAR and anti-Che-1 antibodies. Ctr IgG corresponds to 
immunoprecipitation carried out with control normal mouse IgG. (C) HCT116 cells were transfected with Myc 
empty vector or with Myc-Che-1 expression vector. After 24 hrs of transfection, cells were treated with 1 μM 
Doxo for 4 hrs and total cells extracts were immunoprecipitated with anti-Myc and analyzed by Western blotting 
with the indicated antibodies. Asterisks indicate the positions of poly(ADP-ribosyl)ated Che-1.  
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DISCUSSION 
 
 
Among the various post-translational modifications, poly(ADP-ribosyl)ation is assuming a 
central role in coordinating cell response to stress stimuli. In this work we have explored the 
involvement of PARP activity in DNA damage-induced signalling cascade, showing that 
poly(ADP-ribosyl)ation positively regulates the stabilization of Che-1 protein. 
We demonstrated that Che-1 accumulation induced by 4 hrs Doxo treatment is significantly 
reduced following  inhibition of PARP activity (Figure 12). In particular, impairment in Che-1 
stabilization was observed after pre-treatment with 3-ABA and after short co-treatment with 
the more powerful inhibitor PJ-34, but not after pre-treatment with PJ-34 and its prolonged 
combination with Doxo (4 hours). Although PARP inhibitors are a useful tool to analyze the 
role of poly(ADP-ribosyl)ation reactions in the DDR, it is well established that, when used in 
combination with DNA damaging agents, they can induce an increase in the level of DNA 
damage and further activate DDR. In fact, PARP inhibitors can prevent the release of the 
enzyme from DNA lesions, a necessary event for the completion of the repair, and therefore 
induce DNA damage by triggering the stalling of replication forks (Aguilar-Quesada et al., 
2007; Carrozza et al., 2009; Horton et al., 2005). Consistent with this, pre-treatment of Doxo-
exposed cells with PJ-34 led to an increase in DNA damage level, which probably promoted 
Che-1 stabilization through alternative pathways independent from inhibition of PARP 
activity. This effect was not observed with the less powerful inhibitor 3-ABA, which therefore 
appeared to be a better means to analyze the role of poly(ADP-ribosyl)ation in the first phases 
of the transduction cascade that regulates the adaptative response of the cell to DNA damage.  
Importantly, we showed that Doxo-induced stabilization of Che-1 was significantly impaired 
in PARP-1 knock-out and silenced cells (Figure 13), indicating that PARP-1 is the PARP 
enzyme involved in Che-1 accumulation.  
Previous reports indicate that inhibition of PARP activity reduces transcription of p21 upon 
DNA damage (Wieler et al., 2003) by both p53-independent and p53-dependent mechanisms 
(Madison and Lundblad, 2010). Here we demonstrated that impairment in Che-1 
accumulation by PARP inhibition reduced Che-1 occupancy at p21 promoter and affected the 
expression of the corresponding gene (Figure 14), indicating a role of PARP activity in the 
regulation of Che-1 function in DDR. Notably the Che-1 binding site resides in the proximal 
350 nucleotides of p21 promoter, a region which contains a p53-independent and PARP-
sensitive control element (Madison and Lundblad, 2010). Based on the function of Che-1 in 
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G2/M checkpoint, our data suggest that PARP-1 contributes to the cell cycle arrest upon Doxo 
treatment. 
Poly(ADP-ribosyl)ation modulates ATM phosphorylation cascade in the immediate response 
to DDR (Haince et al., 2007). Che-1 stabilization is regulated by ATM and ATR kinases, and 
inhibition of their activities partially reduces Che-1 accumulation upon Doxo treatment 
(Bruno et al., 2006). PARP-1 might therefore exert its effect on Che-1 accumulation in two 
ways not necessarily mutually exclusive: i) by acting upstream of ATM kinase; ii) by acting 
through a parallel pathway independent from ATM. To distinguish between these two 
hypotheses we performed epistasis experiments and analyzed the effect of the simultaneous 
impairment of PARP and ATM activities on Che-1 level after DNA damage (Figure 16). If 
PARP-1 acted exclusively upstream of ATM, PARP inhibition should not have a further 
effect on Che-1 stabilization respect to ATM inhibition or ATM impairment in A-T cells. On 
the contrary our results clearly indicate that phosphorylation by ATM and poly(ADP-
ribosyl)ation act in independent pathways to modulate Che-1 stabilization. 
In the effort to understand how poly(ADP-ribosyl)ation takes part in Che-1 stabilization, 
immunoprecipitation with anti-PAR antibody was performed. The amount of Che-1 co-
immunoprecipitated with PAR increased as soon as 30 min post Doxo treatment, when the 
total level of Che-1 in the cells was not yet raised (Figure 17). This result suggests a rapid 
association of Che-1 with PAR following DNA damage. Since this association was not due to 
a non-covalent interaction of Che-1 with PAR (Figure 17) and considering that Che-1 is a 
highly acidic protein rich in glutammic and aspartic acid residues, which are preferential 
substrates of PARP catalytic activity, we investigated whether Che-1 could be modified by 
PARP-1. Here we showed that Che-1 directly interacts with PARP-1 (Figure 18) and that 
Che-1 is poly(ADP-ribosyl)ated by PARP-1 (Figure 19).  
The direct interaction was verified by different approaches (Figure 18). Immunofluorescence 
analysis showed a high level of co-localization of PARP-1 and Che-1 in nucleoli of non 
treated cells, in agreement with previous data concerning a nucleolar distribution of PARP-1 
(Meder et al., 2005; Rancourt and Satoh, 2009) and Che-1 (Andersen et al., 2005). The 
functional implication of this interaction in unstimulated cells is not known, but it could be 
correlated to the role of the two proteins in transcription regulation (Bruno et al., 2002; Kraus 
and Lis, 2003). As reported also for other nucleolar proteins (Dellaire and Bazett-Jones, 
2007), delocalization of the two proteins from nucleoli to nucleoplasm occurred upon 
exposure to stress stimuli, although some foci of co-localization of Che-1 and PARP-1 were 
still detectable. Immunoprecipitation experiments confirmed this interaction both in control 
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and in Doxo-exposed cells. In vitro Che-1 directly interacted with recombinant PARP-1 but 
failed to bind highly modified PARP-1, confirming the result of the polymer blot assay and 
excluding the existence of a non-covalent binding between PAR and Che-1. Based on these 
observations, we suggest that the interaction shown in our immunofluorescence and 
immunoprecipitation experiments in Doxo-exposed cells occurs between Che-1 and a pool of 
non-modified or low-modified PARP-1 molecules. Indeed, poly(ADP-ribosyl)ation of PARP-
1 upon DNA damage is an highly dynamic process, in which PARP-1 molecules shuttle 
between an high and a low level of modification because of PARG activity.  
The interaction between the two proteins appears to be the prerequisite for the catalytic 
activity of PARP-1 on Che-1. Such as many other substrates of PARP-1 (Bauer et al., 2001; 
Hassa et al., 2001; Oei et al., 1997; Yung et al., 2004), Che-1 bound the automodification 
domain of PARP-1 (Figure 18). We showed that Che-1 can be covalently modified by PARP-
1 in a in vitro poly(ADP-ribosyl)ation reaction. Further on, immunoprecipitation experiments 
confirmed the existence of a poly(ADP-ribosyl)ated form of Che-1 in Doxo treated cells 
(Figure 19).  
In conclusion, our experiments give a new insight into the mechanisms by which PARP 
activity orchestrates the signalling transduction in DDR. We demonstrate that poly(ADP-
ribosyl)ation positively regulates Che-1 accumulation through an ATM-independent 
mechanism (Figure 20).  
Figure 20. PARP-1 activity promotes 
stabilization of Che-1 in response to DNA 
damage.  
Upon DNA lesions, poly(ADP-ribosyl)ation by 
PARP-1 and phosphorylation by ATM  act in parallel 
pathways to promote stabilization of Che-1. These 
post-translational modifications enable the precise 
control over the level of Che-1 protein in response to 
DNA damage. 
 
 
 
Further experiments will have to address how Che-1 modification by PARP-1 promotes its 
accumulation, and here we discuss some possible mechanisms. One possible explanation is 
that covalent poly(ADP-ribosyl)ation of Che-1 contributes to protect it from proteosomal 
degradation, as has been demonstrated for p53 (Won et al., 2006) and histone proteins 
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(Catalgol et al., 2009). Che-1 seems to be preferentially modified by a low number of ADP-
ribose molecules in vivo, as shown by the absence of a band shift in immunoprecipitations 
(Figure 17B and Figure 19B, C). We can speculate that oligo(ADP-ribosyl)ation of Che-1 is 
important to avoid protein degradation, since it has been reported that interaction with the 
proteasome is restricted to long poly(ADP-ribose) molecules (Mayer-Kuckuk et al., 1999). 
Another possible explanation is that addition of PAR to Che-1 alters its binding properties, for 
example facilitating its interaction with a DDR kinase. Since we demonstrated that poly(ADP-
ribosyl)ation does not modulate Che-1 accumulation through ATM, it could act through 
Chk2, the other kinase strongly involved in Che-1 stabilization. An interaction between PAR 
and Chk2 has never been described, but notably Chk2 from Dictyostelium discoideum 
contains a newly identified PAR-binding motif (Ahel et al., 2008). This region is not 
conserved in human Chk2, but it could still retain the ability to bind PAR by an alternative 
motif. In this case poly(ADP-ribosyl)ation of Che-1 would represent a fine mechanism to 
modulate Che-1 phosphorylation and accumulation.  
Understanding the mechanism through which PARP inhibition acts on Che-1 level in DDR 
can help in the development of new antitumoral agents. Silencing of Che-1 abolishes the 
maintaining of G2/M checkpoint and sensitizes tumor but not normal cells to anticancer drugs 
(Bruno et al., 2006). The potent antitumoral effect of some PARP inhibitors could be due in 
part to their ability to suppress activation of checkpoints after DNA damage induced by 
chemotherapic drugs (Bryant et al., 2005; Fong et al., 2009; Helleday et al., 2008; Rouleau et 
al., 2010; Munoz-Gamez et al., 2010). Our findings suggest that the reduction of Che-1 
stabilization upon PARP inhibition could represent one of the mechanisms by which PARP 
inhibitors exert their antitumoral effects. 
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